glp-1 and pain its derived peptides mediate relief through direct TRPV1 inhibition without affecting thermoregulation gas pains on glp 1

Serum copper monitoring (target range 70-150 g/dL) and ceruloplasmin (20-35 mg/dL) every 8-12 weeks provides objective safety data for patients on GHK-Cu protocols lasting longer than 30 days [5]

doi: Seiwerth S, Brcic L, Vuletic L, et al

Tirzepatide (Mounjaro): Tirzepatide is a newer GLP-1 receptor agonist that has shown promise in both diabetes management and weight loss

However, nausea is most common in the first 8 to 12 weeks of treatment

Hurtado, MD, Mayo Clinic If youre planning surgery, let your anesthesiologist know about your GLP-1 use

When performed by qualified doctors , IV drips are safe and beneficial